DoW Peer Reviewed Medical, Platform Clinical Translation Award

The Platform Clinical Translation Award is offered through the Defense Health Agency as part of the Peer Reviewed Medical Research Program, which is managed under the Congressionally Directed Medical Research Programs. This federal funding initiative is designed to support medical research that directly addresses the health needs of military Service Members, Veterans, and their families. The program operates under statutory authority and has historically received significant congressional appropriations to fund impactful research across a range of health domains. This specific award mechanism represents a new funding opportunity focused on advancing clinical technologies toward real-world application. The primary purpose of the award is to support the translational development of platform-based clinical technologies and early-phase clinical trials. These platform products must be broadly applicable and capable of addressing at least two congressionally directed topic areas identified by the program. The intent is to move promising technologies beyond the preclinical stage and into clinical validation, including first-in-human trials where appropriate. The research must align with one strategic goal within the program’s portfolio framework and demonstrate relevance to military health needs. Funding for this opportunity is substantial, with approximately $30 million allocated to support about two awards. Each award has a maximum total cost cap of $15 million over a performance period of up to four years. Of this, up to $8 million is expected to be available initially, with additional funding contingent upon meeting performance milestones and the availability of future appropriations. Funding may support a wide range of activities including preclinical development, clinical validation, regulatory preparation, and early-phase trials, but it does not support initial product discovery. Eligibility for this program is broad and inclusive. Both domestic and international organizations may apply, including for-profit and nonprofit entities, as well as public and private institutions. Eligible applicants include independent investigators affiliated with these organizations, such as professors, research directors, or equivalent roles. Applications may involve a single principal investigator or a collaborative team of up to three investigators, with one designated as the initiating principal investigator. Cost sharing is not required for participation in this funding opportunity. The application process is structured as a two-step submission. Applicants must first submit a pre-application through the Electronic Biomedical Research Application Portal. Selected applicants will then be invited to submit a full application through either eBRAP or Grants.gov, depending on the organization type. The application requires detailed documentation including a project narrative, supporting data, implementation plans, and various compliance and reporting materials. A mandatory advisory board, including a patient advocate, must also be incorporated into the project design. Applications are evaluated through a rigorous multi-tiered review process that includes both peer review and programmatic review. Evaluation criteria emphasize the potential impact of the platform product, the strength and feasibility of the research strategy, the qualifications of the research team, and the relevance to military health priorities. Additional considerations include the robustness of the implementation plan, the likelihood of successful clinical translation, and the quality of the post-award transition strategy. Key deadlines for the current cycle include a pre-application submission deadline of July 23, 2026, followed by an invitation notification in August and a full application deadline of September 22, 2026. Peer review is expected to occur later in the year, with programmatic review in early 2027 and awards issued by September 2027. The program is expected to recur annually as part of the broader research funding cycle, although this specific award mechanism is newly introduced. Applicants are encouraged to prepare early due to the complexity of submission requirements and registration processes.

Ensure strong preliminary data and clear clinical translation pathway; align with two topic areas and one strategic goal; emphasize milestone driven development and military health relevance